Last updated: September 2, 2026
Amcenestrant, Sanofi's oral selective estrogen receptor degrader, is no longer an active clinical-stage commercial program. Sanofi discontinued development after the Phase 3 AMEERA-3 study failed its primary progression-free-survival endpoint in 2022. The company also stopped the Phase 3 AMEERA-5 study in first-line metastatic breast cancer after a futility assessment. Amcenestrant has no FDA approval, no commercial revenue, no Orange Book listing, and no credible near-term launch scenario.
The asset's remaining value is primarily intellectual property, clinical data, and potential out-licensing value. That value is constrained by the failed pivotal studies, the emergence of approved oral SERDs such as elacestrant, and competition from later-generation agents including camizestrant, imlunestrant, and vepdegestrant.
What is amcenestrant and how does it work?
Amcenestrant, also known as SAR439859, is an oral selective estrogen receptor degrader, or oral SERD, developed for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, breast cancer.
The drug was designed to:
- Bind to the estrogen receptor.
- Promote receptor degradation.
- Suppress estrogen-receptor signaling.
- Treat tumors that remain dependent on estrogen signaling after endocrine therapy.
- Address resistance mechanisms associated with ESR1 mutations.
Amcenestrant was intended to compete with injectable fulvestrant by offering an oral route of administration. The commercial opportunity depended on improving activity after aromatase inhibitor and CDK4/6 inhibitor treatment, particularly in patients with ESR1-mutated tumors.
Sanofi acquired rights to the underlying program through its acquisition of Kymab? No. Amcenestrant was developed internally by Sanofi and was identified in company materials as SAR439859. The program was part of Sanofi's oncology pipeline and received significant investment in Phase 2 and Phase 3 studies.
What is the current development status of amcenestrant?
Amcenestrant development has been discontinued.
| Development item |
Status |
| Active ingredient |
Amcenestrant, SAR439859 |
| Drug class |
Oral selective estrogen receptor degrader |
| Primary indication |
ER+/HER2- advanced or metastatic breast cancer |
| FDA approval |
None |
| EMA approval |
None |
| Phase 3 AMEERA-3 |
Failed primary endpoint |
| Phase 3 AMEERA-5 |
Stopped for futility |
| AMEERA-6 adjuvant program |
Discontinued with the broader program |
| Commercial launch |
None |
| Current revenue |
None attributable to amcenestrant |
| Current development owner |
Sanofi historically; no active commercial program disclosed |
Sanofi reported in July 2022 that AMEERA-3 did not meet its primary endpoint. The study evaluated amcenestrant against physician's choice of endocrine therapy in patients with ER+/HER2- advanced or metastatic breast cancer after prior treatment. The failure removed the principal registration path for the monotherapy program (Sanofi, 2022a).
Sanofi later reported that AMEERA-5, which evaluated amcenestrant in combination with palbociclib in the first-line setting, was stopped after an independent data monitoring committee determined that the study was unlikely to meet its primary endpoint (Sanofi, 2022b).
The company subsequently ended development across the amcenestrant program. No later clinical restart, licensing transaction, regulatory filing, or commercial partnership has changed that status.
Why did amcenestrant fail in Phase 3?
The central issue was insufficient clinical differentiation in a competitive treatment setting.
AMEERA-3 tested whether amcenestrant could improve progression-free survival over physician's-choice endocrine therapy in previously treated advanced breast cancer. The study did not demonstrate a statistically significant benefit in the overall study population. That result weakened the case for broad use in post-CDK4/6 treatment and limited the potential for an indication based on ESR1 mutation status.
The program also faced technical and market pressures:
Activity after CDK4/6 inhibitor treatment
Patients enrolled in AMEERA-3 had advanced disease and prior endocrine-based treatment. This population includes tumors with multiple resistance mechanisms. A drug must produce a clear benefit over available endocrine therapy, chemotherapy, or emerging targeted regimens to support regulatory approval and reimbursement.
Competition from oral SERDs
Elacestrant became the first oral SERD approved in the United States. The FDA approved Orserdu in January 2023 for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer with activating ESR1 mutations after at least one line of endocrine therapy, based on the EMERALD study (FDA, 2023).
That approval established a regulatory and commercial benchmark that amcenestrant did not meet.
First-line combination risk
AMEERA-5 tested amcenestrant with palbociclib against letrozole with palbociclib. The control arm reflected a well-established first-line endocrine backbone. A new SERD needed to show a substantial improvement over an aromatase inhibitor in combination with a CDK4/6 inhibitor. The futility stop indicated that the probability of achieving that result was inadequate.
Uncertain biomarker strategy
ESR1 mutations provide a rational biomarker for oral SERD therapy, but not every SERD has equivalent activity across ESR1 mutation subtypes or resistance contexts. The development program did not establish a sufficiently strong biomarker-defined population to preserve a viable regulatory path after the overall Phase 3 failure.
What FDA regulatory status does amcenestrant have?
Amcenestrant has no FDA approval and no publicly known New Drug Application approval or pending commercial application.
| FDA regulatory question |
Answer |
| Approved product name |
None |
| FDA approval date |
None |
| Approved indication |
None |
| Breakthrough Therapy designation |
No confirmed approval-linked designation |
| Fast Track approval |
No confirmed approval-linked designation |
| NDA approval |
None |
| Orange Book listing |
None |
| Authorized generic |
None |
| Current clinical development |
Discontinued |
Because amcenestrant was never approved, it has no FDA-granted five-year new chemical entity exclusivity, three-year clinical investigation exclusivity, or pediatric exclusivity. Patent rights, if still enforceable, would be separate from FDA regulatory exclusivity.
What patents protect amcenestrant?
The public record does not establish an active commercial patent estate that can support a product launch or Orange Book-based litigation strategy.
Potential protection for amcenestrant would ordinarily include:
- Composition-of-matter patents covering the molecule.
- Salt, polymorph, and crystalline-form patents.
- Pharmaceutical composition patents.
- Treatment patents for ER+/HER2- breast cancer.
- Combination patents covering amcenestrant with palbociclib or other CDK4/6 inhibitors.
- Biomarker patents involving ESR1-mutated tumors.
- Manufacturing and process patents.
Sanofi and affiliated entities may hold patent rights covering amcenestrant or related compounds. However, patent ownership, expiration, terminal disclaimers, prosecution status, and enforceability must be assessed patent by patent in the relevant jurisdiction. No approved product means there is no Orange Book patent list for amcenestrant and no standard Paragraph IV pathway directed against an approved reference drug.
How many patents cover amcenestrant?
There is no reliable public basis for stating a single number of enforceable patents covering amcenestrant. Patent-family counts can materially overstate commercial protection because they may include abandoned applications, foreign counterparts, divisional applications, expired claims, or patents that do not cover the final clinical formulation.
The most important patent question is not the number of published applications. It is whether an unexpired, enforceable composition-of-matter claim covers amcenestrant in a commercially relevant jurisdiction and whether Sanofi has a reason to maintain that protection after program termination.
When does amcenestrant lose patent exclusivity?
A definitive patent expiration date cannot be stated from the discontinued clinical program alone. Composition-of-matter patent terms generally run approximately 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and jurisdiction-specific rules.
Because amcenestrant has no approved product, it cannot currently receive U.S. patent-term extension tied to an approved regulatory application. Any remaining patent term therefore has declining strategic value unless the asset is revived or licensed for a new indication.
What patent litigation affects amcenestrant?
No major public Paragraph IV litigation, ANDA litigation, or patent settlement involving amcenestrant has been reported.
That result is consistent with the product's status:
- No approved amcenestrant reference product exists.
- No generic applicant has a commercial ANDA target.
- Sanofi has no marketed amcenestrant product requiring Orange Book enforcement.
- The development program ended before regulatory filing.
Any future dispute would more likely involve patent ownership, license scope, research-use rights, or a revived development program than conventional generic litigation.
What is the market projection for amcenestrant?
The base-case market projection is zero commercial sales through the medium term because the program is discontinued and has no approval path.
| Scenario |
Probability assessment |
Market implication |
| No further development |
Base case |
No product revenue |
| Sanofi restarts development |
Low |
Requires new clinical strategy and capital |
| Out-license to another oncology company |
Low to very low |
Possible asset value, but high redevelopment burden |
| Biomarker-defined revival |
Low |
Would require convincing retrospective or new prospective data |
| Generic or biosimilar competition |
Not applicable |
No approved reference product |
| Commercial launch before 2030 |
Remote |
No active Phase 3 or regulatory program |
A revival would require a new value proposition, such as:
- A clearly defined ESR1-mutated population.
- Stronger activity against specific ESR1 resistance mutations.
- A combination strategy with a CDK4/6 inhibitor or targeted agent.
- A differentiated safety or dosing profile.
- New evidence from archived clinical samples.
- A development plan that avoids direct comparison with stronger late-stage oral SERD competitors.
The redevelopment cost would be high. A new Phase 3 strategy in metastatic breast cancer could require several hundred million dollars, excluding manufacturing, regulatory, and commercialization costs. The failed AMEERA studies would also increase investor and partner demands for mechanistic and biomarker validation.
How does amcenestrant compare with competing oral SERDs?
Amcenestrant entered a class that has become more competitive since its discontinuation.
| Drug |
Developer |
Development or regulatory status |
Key differentiation |
| Amcenestrant |
Sanofi |
Discontinued |
Failed Phase 3 development |
| Elacestrant |
Radius Health and Menarini |
FDA-approved in 2023 |
ESR1-mutated advanced or metastatic breast cancer |
| Camizestrant |
AstraZeneca |
Clinical development |
Oral SERD with biomarker-focused development |
| Imlunestrant |
Eli Lilly |
Clinical development through 2024 |
Oral SERD development in early and advanced disease |
| Vepdegestrant |
Arvinas and Pfizer |
Clinical development |
Oral estrogen receptor degrader program |
| Giredestrant |
Roche |
Clinical development history |
Broad oral SERD and early breast cancer development |
Elacestrant has the strongest regulatory position because it is already approved. Camizestrant, imlunestrant, and vepdegestrant have benefited from continued development and, in some cases, more targeted trial designs.
Amcenestrant's comparative weaknesses are its failed Phase 3 record, discontinued program, lack of regulatory exclusivity, and absence of a current commercial sponsor. Its potential advantage is that clinical data and existing manufacturing knowledge could reduce early redevelopment costs if Sanofi or a partner identified a credible niche.
What generic entry risks exist for amcenestrant?
Generic entry is not the relevant near-term risk because amcenestrant has never reached the market.
The primary risks are:
- Clinical redevelopment risk.
- Patent expiration before a potential approval.
- Loss of commercial differentiation.
- Competition from approved and late-stage oral SERDs.
- Reimbursement pressure in the ESR1-mutated breast cancer segment.
- Difficulty securing a partner willing to fund a new pivotal program.
- Potential inability to obtain meaningful regulatory exclusivity after a late-stage restart.
If amcenestrant were revived and approved, generic entry would depend on the surviving composition-of-matter and formulation patents, any regulatory exclusivity attached to the new approval, and the scope of method-of-use claims. A Paragraph IV challenge would become possible only after approval and listing of relevant patents in the Orange Book.
What is the licensing and transaction outlook for amcenestrant?
No major licensing transaction for amcenestrant has been publicly disclosed following Sanofi's discontinuation decision.
An out-license would be difficult but not impossible. A potential partner would likely discount the asset heavily because:
- The principal metastatic Phase 3 study failed.
- The first-line combination study was stopped for futility.
- The program lacks a current regulatory path.
- Competing SERDs have advanced.
- Patent value may decline during redevelopment.
- The historical safety, pharmacokinetic, and efficacy package may not support a narrow approval without new trials.
The most plausible transaction structure would be an option-based agreement, regional license, or low upfront payment with development milestones rather than a large acquisition. A partner would likely seek rights to archived clinical data, biomarker samples, manufacturing documentation, and all relevant patent families.
What geographic coverage and manufacturing barriers apply?
The clinical program was designed for global development, but geographic clinical reach does not create commercial protection. Any remaining patent rights must be evaluated separately in the United States, Europe, Japan, China, and other jurisdictions.
Manufacturing barriers are likely lower than for biologics because amcenestrant is a small molecule. The key issues would be:
- Re-establishing qualified active pharmaceutical ingredient manufacturing.
- Confirming process reproducibility.
- Revalidating drug substance and drug product specifications.
- Preserving tablet stability data.
- Supporting commercial-scale supply.
- Rebuilding regulatory chemistry, manufacturing, and controls documentation.
Manufacturing is unlikely to be the primary obstacle. Clinical efficacy, patent life, and competitive positioning are the decisive barriers.
Key Takeaways
- Amcenestrant is a discontinued Sanofi oral SERD.
- AMEERA-3 failed its Phase 3 primary endpoint.
- AMEERA-5 was stopped for futility.
- The asset has no FDA approval, NDA approval, Orange Book listing, or commercial revenue.
- No meaningful Paragraph IV litigation or generic launch scenario exists.
- Patent rights may remain, but their commercial value depends on unexpired claims and a viable redevelopment plan.
- Elacestrant has established the regulatory benchmark for oral SERDs in ESR1-mutated breast cancer.
- The base-case market projection for amcenestrant is zero.
- A restart or out-license would require a new biomarker-led strategy and substantial clinical investment.
- The asset's residual value is primarily optionality around clinical data, intellectual property, and potential niche redevelopment.
FAQs About Amcenestrant
Is amcenestrant still being developed by Sanofi?
No. Sanofi discontinued the amcenestrant clinical program after negative or futile Phase 3 outcomes in 2022.
Was amcenestrant approved by the FDA?
No. Amcenestrant has never received FDA approval and has no approved indication.
Can patients currently obtain amcenestrant commercially?
No. There is no commercial amcenestrant product and no established FDA-approved access pathway.
Is amcenestrant a biosimilar or generic drug?
No. Amcenestrant is a synthetic small-molecule investigational drug. It is not a biologic, biosimilar, or marketed generic.
Could amcenestrant return to clinical development?
A restart is technically possible but commercially unlikely. It would require a new sponsor or Sanofi commitment, a differentiated biomarker strategy, fresh clinical evidence, and sufficient remaining patent or regulatory value.
References
-
Sanofi. (2022a). Sanofi provides update on AMEERA-3 Phase 3 study of amcenestrant in patients with advanced or metastatic breast cancer. Sanofi corporate communications.
-
Sanofi. (2022b). Sanofi provides update on AMEERA-5 Phase 3 study of amcenestrant in first-line treatment of ER+/HER2- advanced or metastatic breast cancer. Sanofi corporate communications.
-
U.S. Food and Drug Administration. (2023). FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA.
-
ClinicalTrials.gov. (n.d.). AMEERA clinical studies of amcenestrant. U.S. National Library of Medicine.
-
Sanofi. (2022c). 2022 full-year results and pipeline update. Sanofi.
